October 11, 2019 | Deborah Kotz
Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
Wednesday, July 31, 2019
Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate
Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).
Tuesday, February 19, 2019
Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.
Monday, October 29, 2018
October is Breast Cancer Awareness Month, and researchers at the University of Maryland School of Medicine (UMSOM) continue in their work to help combat this disease that impacts more than 315,000 women in the U.S. each year.
Monday, October 08, 2018
High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy
The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.
Monday, September 24, 2018
University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference
The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.
Monday, May 14, 2018
Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center
Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).
Wednesday, May 10, 2017
Under normal conditions, the CHD4 protein is helpful: it stops cells from transcribing faulty DNA, thereby eliminating potential mutation. However, in colon cancer and perhaps other kinds of cancer as well, it appears that this protein becomes a kind of double agent, working for the enemy.
Tuesday, October 11, 2016
Researchers Identify Novel Mechanism In Combination Drug Therapy For Acute Myeloid Leukemia, Other Cancers
Researchers have discovered a novel mechanism in a combination drug therapy that shows potential as a new approach for treating acute myeloid leukemia (AML) and many other cancers. When combined, these agents cause interactions that significantly disrupt cancer cells’ ability to survive DNA damage, according to a preclinical study published today in the journal Cancer Cell.
Friday, January 15, 2016
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).